Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable, chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons and paralysis of skeletal muscles. Reactivating dysfunctional areas is under earnest investigation utilizing various approaches. Here we present an innovative gene-cell construct aimed at reviving inert structure and function. Human umbilical cord blood cells (hUCBCs) transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were transplanted into transgenic ALS mice models. Significant improvement in behavioral performance (open-field and grip-strength tests), as well as increased life-span was observed in rodents treated with NCAM-VEGF or NCAM-GDNF co-transfected cells. Active trans-gene expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-cell therapy model yielded prominent symptomatic control and prolonged life-time in ALS. Incredible survivability of xeno-transpanted cells was also observed without any immune-suppression. These results suggest that engineered hUCBCs may offer effective gene-cell therapy in ALS.
Keywords: Adeno-virus, amyotrophic lateral sclerosis (ALS), gene-cell therapy, glial cell-derived neuro-trophic factor (GDNF), human umbilical cord blood cell (hUCBC), human umbilical cord blood mono-nuclear cell (hUCB-MC), neural cell adhesion molecule (NCAM), vascular endothelial growth factor (VEGF), viral vector.
Current Gene Therapy
Title:Symptomatic Improvement, Increased Life-Span and Sustained Cell Homing in Amyotrophic Lateral Sclerosis After Transplantation of Human Umbilical Cord Blood Cells Genetically Modified with Adeno-Viral Vectors Expressing a Neuro-Protective Factor and a Neural Cell Adhesion Molecule
Volume: 15 Issue: 3
Author(s): Rustem Robertovich Islamov, Albert Anatolyevich Rizvanov, Marat Alexandrovich Mukhamedyarov, Ilnur Ildusovich Salafutdinov, Ekaterina Evgenevna Garanina, Valeria Yuryevna Fedotova, Valeria Vladimirovna Solovyeva, Yana Olegovna Mukhamedshina, Zufar Zufarovich Safiullov, Andrey Alexandrovich Izmailov, Daria Sergeevna Guseva, Andrey Lvovich Zefirov, Andrey Pavlovich Kiyasov and Andras Palotas
Affiliation:
Keywords: Adeno-virus, amyotrophic lateral sclerosis (ALS), gene-cell therapy, glial cell-derived neuro-trophic factor (GDNF), human umbilical cord blood cell (hUCBC), human umbilical cord blood mono-nuclear cell (hUCB-MC), neural cell adhesion molecule (NCAM), vascular endothelial growth factor (VEGF), viral vector.
Abstract: Amyotrophic lateral sclerosis (ALS) is an incurable, chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons and paralysis of skeletal muscles. Reactivating dysfunctional areas is under earnest investigation utilizing various approaches. Here we present an innovative gene-cell construct aimed at reviving inert structure and function. Human umbilical cord blood cells (hUCBCs) transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were transplanted into transgenic ALS mice models. Significant improvement in behavioral performance (open-field and grip-strength tests), as well as increased life-span was observed in rodents treated with NCAM-VEGF or NCAM-GDNF co-transfected cells. Active trans-gene expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-cell therapy model yielded prominent symptomatic control and prolonged life-time in ALS. Incredible survivability of xeno-transpanted cells was also observed without any immune-suppression. These results suggest that engineered hUCBCs may offer effective gene-cell therapy in ALS.
Export Options
About this article
Cite this article as:
Islamov Robertovich Rustem, Rizvanov Anatolyevich Albert, Mukhamedyarov Alexandrovich Marat, Salafutdinov Ildusovich Ilnur, Garanina Evgenevna Ekaterina, Fedotova Yuryevna Valeria, Solovyeva Vladimirovna Valeria, Mukhamedshina Olegovna Yana, Safiullov Zufarovich Zufar, Izmailov Alexandrovich Andrey, Guseva Sergeevna Daria, Zefirov Lvovich Andrey, Kiyasov Pavlovich Andrey and Palotas Andras, Symptomatic Improvement, Increased Life-Span and Sustained Cell Homing in Amyotrophic Lateral Sclerosis After Transplantation of Human Umbilical Cord Blood Cells Genetically Modified with Adeno-Viral Vectors Expressing a Neuro-Protective Factor and a Neural Cell Adhesion Molecule, Current Gene Therapy 2015; 15 (3) . https://dx.doi.org/10.2174/1566523215666150126122317
DOI https://dx.doi.org/10.2174/1566523215666150126122317 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ketamine: New Indications for an Old Drug
Current Drug Targets Inactivation of Parathyroid Hormone: Perspectives of Drug Discovery to Combating Hyperparathyroidism
Current Molecular Pharmacology Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Metabolic Control of Glia-Mediated Neuroinflammation
Current Alzheimer Research Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Editorial (Thematic Issue: Microglia - A Therapeutic Target in Neurological Diseases and Disorders)
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Biological Activity of Some Volatile Diterpenoids
Current Bioactive Compounds Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment
CNS & Neurological Disorders - Drug Targets Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms
Current Protein & Peptide Science